Browsing by Author "Annane, Djillali"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    A global perspective on vasoactive agents in shock
    (2018) Annane, Djillali; Ouanes-Besbes, Lamia; de Backer, Daniel; Du, Bin; Gordon, Anthony C.; Hernández P., Glenn; Olsen, Keith M.; Osborn, Tiffany M.; Peake, Sandra; Russell, James A.; Cavazzoni, Sergio Zanotti
  • Thumbnail Image
    Item
    Current use of inotropes in circulatory shock
    (2021) Scheeren, Thomas W. L.; Bakker, Jan; Hernández P., Glenn; Kaufmann, Thomas; Annane, Djillali; Asfar, Pierre; Boerma, E. Christiaan; Cecconi, Maurizio; Chew, Michelle S.; Cholley, Bernard
    Abstract Background Treatment decisions on critically ill patients with circulatory shock lack consensus. In an international survey, we aimed to evaluate the indications, current practice, and therapeutic goals of inotrope therapy in the treatment of patients with circulatory shock. Methods From November 2016 to April 2017, an anonymous web-based survey on the use of cardiovascular drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 14 questions focused on the profile of respondents, the triggering factors, first-line choice, dosing, timing, targets, additional treatment strategy, and suggested effect of inotropes. In addition, a group of 42 international ESICM experts was asked to formulate recommendations for the use of inotropes based on 11 questions. Results A total of 839 physicians from 82 countries responded. Dobutamine was the first-line inotrope in critically ill patients with acute heart failure for 84% of respondents. Two-thirds of respondents (66%) stated to use inotropes when there were persistent clinical signs of hypoperfusion or persistent hyperlactatemia despite a supposed adequate use of fluids and vasopressors, with (44%) or without (22%) the context of low left ventricular ejection fraction. Nearly half (44%) of respondents stated an adequate cardiac output as target for inotropic treatment. The experts agreed on 11 strong recommendations, all of which were based on excellent (> 90%) or good (81–90%) agreement. Recommendations include the indications for inotropes (septic and cardiogenic shock), the choice of drugs (dobutamine, not dopamine), the triggers (low cardiac output and clinical signs of hypoperfusion) and targets (adequate cardiac output) and stopping criteria (adverse effects and clinical improvement). Conclusion Inotrope use in critically ill patients is quite heterogeneous as self-reported by individual caregivers. Eleven strong recommendations on the indications, choice, triggers and targets for the use of inotropes are given by international experts. Future studies should focus on consistent indications for inotrope use and implementation into a guideline for circulatory shock that encompasses individualized targets and outcomes.
  • Thumbnail Image
    Item
    Current use of vasopressors in septic shock
    (2019) Scheeren, Thomas W. L.; Bakker, Jan; Backer, Daniel de; Annane, Djillali; Asfar, Pierre; Boerma, E. Christiaan; Cecconi, Maurizio; Dubin, Arnaldo; Dünser, Martin W.; Duranteau, Jacques; Gordon, Anthony C.; Hamzaoui, Olfa; Hernández P., Glenn; Leone, Marc; Levy, Bruno; Martin, Claude; Mebazaa, Alexandre; Monnet, Xavier; Morelli, Andrea; Payen, Didier; Pearse, Rupert; Pinsky, Michael R.; Radermacher, Peter; Reuter, Daniel; Saugel, Bernd; Sakr, Yasser; Singer, Mervyn; Squara, Pierre; Vieillard‑Baron, Antoine; Vignon, Philippe; Vistisen, Simon T.; Horst, Iwan C. C. van der; Vincent, Jean‑Louis; Tebou, Jean‑Louis
  • Thumbnail Image
    Item
    Equilibrating SSC guidelines with individualized care
    (2021) Vincent, J. L.; Singer, Mervyn; Einav, Sharon; Moreno, Rui; Wendon, Julia; Teboul, Jean-Louis; Bakker, Jan; Hernández P., Glenn; Annane, Djillali; Man, Angélique M. E. de
  • Thumbnail Image
    Item
    Pannexin-1 channel opening is critical for COVID-19 pathogenesis
    (CELL PRESS, 2021) Luu, Ross; Valdebenito, Silvana; Scemes, Eliana; Cibelli, Antonio; Spray, David C.; Rovegno, Maximiliano; Tichauer, Juan; Cottignies Calamarte, Andrea; Rosenberg, Arielle; Capron, Calude; Belouzard, Sandrine; Dubuisson, Jean; Annane, Djillali; de la Grandmaison, Geoffroy Lorin; Cramer Borde, Elisabeth; Bomsel, Morgane; Eugenin, Eliseo
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly rampaged worldwide, causing a pandemic of coronavirus disease (COVID-19), but the biology of SARS-CoV-2 remains under investigation. We demonstrate that both SARS-CoV-2 spike protein and human coronavirus 229E (hCoV-229E) or its purified S protein, one of the main viruses responsible for the common cold, induce the transient opening of Pannexin-1 (Panx-1) channels in human lung epithelial cells. However, the Panx-1 channel opening induced by SARS-CoV-2 is greater and more prolonged than hCoV-229E/S protein, resulting in an enhanced ATP, PGE(2), and IL-1 beta release. Analysis of lung lavages and tissues indicate that Panx-1 mRNA expression is associated with increased ATP, PGE(2), and IL-1 beta levels. Panx-1 channel opening induced by SARS-CoV-2 spike protein is angiotensin-converting enzyme 2 (ACE-2), endocytosis, and furin dependent. Overall, we demonstrated that Panx-1 channel is a critical contributor to SARS-CoV-2 infection and should be considered as an alternative therapy.